Life Sciences: What's new in France?
December 21, 2020
Read more about the recent developments in the life sciences sector in France.
Content:
- The Santen decision: bad news for drug repurposing
- Foreign direct investment control in France in time of COVID
- Decree of 25 August 2020 on the harmonization of market access conditions: will simplification benefit to the stakeholders?
- Avastin/Lucentis case: French Competition Authority imposes record fine of 444 million euros on Novartis and Roche for alleged abuse of collective dominant position
- The new French anti-gift regulation is live since 1st October 2020
Related Professionals
